146
Participants
Start Date
October 4, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
TRK-950
5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
Ramucirumab
8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Paclitaxel
80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
RECRUITING
Seoul National University Bundang Hospital, Seongnam-si
RECRUITING
Kyungpook National University Chilgok Hospital, Daegu
RECRUITING
Chonnam National University Hwasun Hospital, Hwasun
RECRUITING
Texas Oncology Plano East, Plano
RECRUITING
Texas Oncology Plano West, Plano
RECRUITING
Texas Oncology Dallas Methodist, Dallas
RECRUITING
Texas Oncology Dallas Medical City, Dallas
RECRUITING
Texas Oncology Dallas Presbyterian, Dallas
RECRUITING
Texas Oncology Methodist Charlton Cancer Center, Dallas
RECRUITING
Texas Oncology-Sammons Cancer Center, Dallas
RECRUITING
Texas Oncology Arlington North, Arlington
RECRUITING
Texas Oncology Bedford, Bedford
RECRUITING
Texas Oncology Grapevine, Grapevine
RECRUITING
Texas Oncology Fort Worth Cancer Center, Fort Worth
RECRUITING
University of California, Los Angeles, Santa Monica
RECRUITING
City of Hope, Duarte
RECRUITING
City of Hope at Orange County Lennar Foundation Cancer Center, Irvine
RECRUITING
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama
RECRUITING
Saitama Prefectural Hospital Organization Saitama Cancer Center, Shinden
RECRUITING
Shizuoka Cancer Center, Nagaizumi-cho
RECRUITING
National Cancer Center Hospital, Chūōku
RECRUITING
Osaka International Cancer Institute, Chūōku
RECRUITING
National Cancer Center Hospital East, Kashiwa
RECRUITING
The Cancer Institute Hospital of JFCR, Kōtoku
RECRUITING
Severance Hospital, Seoul
RECRUITING
ASAN Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
Toray Industries, Inc
INDUSTRY